| ￥5800 | |
| Z04434-100 | |
|
|
|
|
|
|
|
|
|
| Species | Human | ||||||
| Protein Construction |
|
||||||
| Conjugate | Biotin | ||||||
| Purity |
> 95% as determined by BisTris PAGE > 95% as determined by HPLC |
||||||
| Endotoxin Level | Less than 1EU per μg by the LAL method. | ||||||
| Expression System | HEK293 | ||||||
| Theoretical Molecular Weight | 59.1 kDa | ||||||
| Apparent Molecular Weight | Due to glycosylation, the protein migrates to 68-75 kDa based on Bis-Tris PAGE result. | ||||||
| Formulation | Lyophilized from 0.22μm filtered solution in PBS (pH 7.4). | ||||||
| Reconstitution | Centrifuge the tube before opening. Reconstituting to a concentration more than 100 μg/ml is recommended. Dissolve the lyophilized protein in distilled water. | ||||||
| Storage & Stability | Upon receiving, the product remains stable up to 6 months at -20 °C or below. Upon reconstitution, the product should be stable for 3 months at -80 °C. Avoid repeated freeze-thaw cycles. |
The purity of CLEC2D hFc Chimera[Biotin], Avi, Human is greater than 95% as determined by SEC-HPLC. »
CLEC2D hFc Chimera[Biotin], Avi, Human on Bis-Tris PAGE under reduced condition. The purity is greater than 95%. »
| Target Background | C-type lectin domain family 2, member D (CLEC2D) is implicated in the immune response. Pre-eclampsia and HIV infection have opposing immune responses. The contrasting expression of CLEC2D in HIV infection and pre-eclampsia is demonstrative of the immunosuppressive and pro-inflammatory roles of the respective pathologies. |
| Synonyms | LLT-1; CLAX; LLT1; OCIL; CLEC2D; CLAXLLT-1; OCILmember D |
For research use only. Not intended for human or animal clinical trials, therapeutic or diagnostic use.
